BIB ProShares Ultra NASDAQ Biotechnology

*Unless otherwise stated, data provided by FactSet.

BIB Fund Description

BIB provides 2x daily exposure to a modified market-cap-weighted index of biotechnology and pharmaceutical companies listed on NASDAQ.

BIB Factset Analytics Insight

BIB, having been around since 2010, is a leveraged play on the NASDAQ Biotechnology Index (which is also tracked in unlevered form by iShares' IBB), and is heavily focused on NASDAQ’s biotechnology and pharmaceutical firms with a large-cap bias. The fund gains its 2x leveraged exposure to the index through several financial instruments (i.e. equity securities, derivatives and money-market instruments), and rebalances its exposure daily. Like all geared funds that rebalance daily, BIB is meant for short-term trading since compounding effects over the long-term could create vast differences from expected returns—for good or for ill.

PERFORMANCE [as of 10/04/22] 1 MONTH 3 MONTHS YTD 1 YEAR 3 YEARS 5 YEARS 10 YEARS
BIB 2.21% 2.51% -36.18% -40.99% 6.77% -4.07% 11.98%
BIB (NAV) 2.17% 2.64% -36.08% -40.97% 6.79% -4.04% 12.00%
NASDAQ Biotechnology Index 1.75% 2.94% -16.18% -18.93% 8.69% 2.64% 10.45%
N/A -- -- -- -- -- -- --
All returns over 1 year are annualized. All returns are total returns unless otherwise stated.

BIB Summary Data

ProShares
04/07/10
Open-Ended Fund
0.95%
$90.57M
0.24%

BIB Portfolio Data

0.00%
12/22/22

BIB Index Data

Market Cap
NASDAQ - Listed
N/A

BIB Fund Structure

Yes
No
-- / --
N/A
N/A
Low
2
Daily

BIB Tax Exposures

20.00% / 39.60%
--
No

BIB Factset Analytics Block Liquidity

As of 10/05/22
5
4
3
2
1

This measurement shows how easy it is to trade a $1 million USD block of BIB. BIB is rated a N/A out of 5.

BIB Tradability

31,599
$1.65M
25,251
$1.41M
0.24%
$0.13
0.02%
0.41% / -1.44%
None
99.93%
50,000
0.51
0.01%
--
1,272
$51.86
N/A